Quest Diagnostics Inc.’s stock rose 3% early Tuesday, after the company posted better-than-expected first-quarter earnings ...

Quest Diagnostics stock remains a "safe haven," an analyst said Tuesday after the company topped first-quarter expectations.

Quest Diagnostics Q1 2025 revenue rose to $2.65 billion with EPS of $2.21, exceeding expectations; full-year guidance for ...

Q1 2025 Management View Jim Davis, CEO, reported a 12% revenue growth in Q1 2025, attributed to contributions from acquisitions, large enterprise accounts, and the advanced diagnostics portfolio.

Laboratory operator Quest Diagnostics beat Wall Street estimates for first-quarter profit on Tuesday, helped by robust demand for its diagnostic tests.

Quest Diagnostics backs FY25 adjusted EPS view $9.55-$9.80, consensus $9.69 Backs FY25 revenue view $10.7B-$10.85B, consensus $10.78B. Backs FY25 capital expenditures $500M.

U.S. stocks were higher, with the Dow Jones index gaining around 600 points on Tuesday. Shares of Quest Diagnostics ...

DGX's first-quarter 2025 performance is likely to have been supported by the ongoing utilization of its Advanced Diagnostics ...

Quest Diagnostics expects full-year earnings in the range of $9.55 to $9.80 per share, with revenue in the range of $10.7 billion to $10.85 billion. This story was generated by Automated Insights ( ...

The company’s cash flow from operations more than doubled to $314 million in Q1, up from $154 million a year ago. Capital expenditures increased 11.9% to $117 million. Quest Diagnostics will hold a ...

The company said during a conference call following release of its Q1 2025 results that it purchases roughly 80 percent of its supplies from sources within the US.